Kessler Investment Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Kessler Investment Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,373	Closed	-$622K	–	100
2025 Q4	$622K	Hold	1,373	–	–	0.26%	51
2025 Q3	$538K	Hold	1,373	–	–	0.23%	51
2025 Q2	$611K	Hold	1,373	–	–	0.25%	48
2025 Q1	$666K	Hold	1,373	–	–	0.33%	47
2024 Q4	$553K	Sell	1,373 -12,397	-90%	-$5.75M	0.26%	49
2024 Q3	$6.4M	Sell	13,770 -268	-2%	-$129K	3.29%	12
2024 Q2	$6.58M	Buy	14,038 +526	+4%	+$228K	3.55%	6
2024 Q1	$5.65M	Buy	13,512 +517	+4%	+$219K	3.5%	13
2023 Q4	$5.29M	Sell	12,995 -314	-2%	-$116K	3.24%	15
2023 Q3	$4.63M	Buy	13,309 +39	+0.3%	+$13.6K	3.88%	10
2023 Q2	$4.67M	Buy	+13,270	New	+$4.47M	3.29%	15

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Kessler Investment Group's VRTX Position: Q1 2026 in Review

Kessler Investment Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 1,373 shares — an estimated $622K sold.

Kessler Investment Group first reported a position in VRTX in Q2 2023 and held it in 11 quarters. The position peaked at $6.58M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Kessler Investment Group reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Kessler Investment Group sold 1,373 Vertex Pharmaceuticals shares in Q1 2026, an estimated $622K.
Kessler Investment Group first reported a position in Vertex Pharmaceuticals in Q2 2023 and held it in 11 quarters.
Kessler Investment Group's Vertex Pharmaceuticals position peaked at $6.58M in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Kessler Investment Group's 13F filing for Q1 2026, filed 10 Apr 2026.